Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy

References

• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
   PubMed Web of Science ®Google Scholar
• Schutt P, Passon J, Ebeling P et al. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. Eur J Haematol 2007; 78: 93–101.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A et al. BEAM chemotherapy andautologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588–595.
   PubMed Web of Science ®Google Scholar
• Crump M, Baetz T, Couban S et al. Gemcitabine, dexamethasone,and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 2004; 101: 1835–1842.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for trans-plant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776–3785.
   PubMed Web of Science ®Google Scholar
• Soussain C, Souleau B, Gabarre J et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leukemia Lymphoma 1999; 33: 543–550.
   PubMed Web of Science ®Google Scholar
• Chen CI, Roitman D, Tsang R et al. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 30: 885–891.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S et al. ESHAP — an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244—.
   PubMed Web of Science ®Google Scholar
• Crump M, Smith AM, Brandwein J et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol 1993; 11: 704–711.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lym-phoma. N Engl J Med 1993; 329: 987–994.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Kakouros N, Qian W et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol 2005; 130: 363–372.
   PubMed Web of Science ®Google Scholar
• Simpson L, Ansell SM, Colgan JP et al. Effectiveness of second linesalvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexametha-sone. Leukemia Lymphoma 2007; 48: 1332–1337.
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M Truemper L, Osterborg A et al. MabThera International Trial Group. CHOP-like chemotherapy plus ritux-imab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 2006; 7: 379–391.
   Google Scholar
• Kewalramani T, Zelenetz AD, Nimer SD et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684–3688.
   PubMed Web of Science ®Google Scholar
• Vellenga E, van Putten WLJ, van't Veer MB et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20 + NHL: a prospective randomized HOVON trial. Blood 2008; 111: 537–543.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Schmitz N, Mounier N et al. R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL Study. ASH Annual Meeting Abstracts 2007; 110: 517—.
   Google Scholar
• Blay JY, Gomez F, Sebban C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood 1998; 92: 3562–3568.
   PubMed Web of Science ®Google Scholar
• Guglielmi C, Martelli M, Federico M et al. Risk-assessment in diffuse large cell lymphoma at first relapse. A study by the Italian Intergroup for Lymphomas. Haematologica 2001; 86: 941–950.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Zelenetz AD, Kewalramani T et al. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003; 102: 1989–1996.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 2002; 8: 68–74.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Zelenetz AD, Kewalramani T et al. Cell of origin, germinal center versus nongerminal center, determined by immu-nohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005; 106: 3383–3385.
   PubMed Web of Science ®Google Scholar
• Haarer CF, Roberts RA, Frutiger YM et al. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006; 130: 1819–1824.
   PubMed Web of Science ®Google Scholar
• Andreadis C, Gimotty PA, Wahl P et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. Blood 2007; 109: 3409–3416.
   PubMed Web of Science ®Google Scholar
• Colwill R, Crump M, Couture F et al. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol 1995; 13: 396–402.
   PubMed Web of Science ®Google Scholar
• Stamatoullas A, Fruchart C, Bastit D et al. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer 1996; 77: 2302–2307.
   PubMed Web of Science ®Google Scholar
• O'Reilly S, Hoskins P, Klimo P, Connors J. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2: 17–23.
   PubMed Web of Science ®Google Scholar